Eleven Biotherapeutics, Inc. (EBIO) Posts Earnings Results
Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) announced its quarterly earnings data on Monday. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, Morningstar.com reports. Eleven Biotherapeutics had a return on equity of 7.73% and a net margin of 11.28%.
Shares of Eleven Biotherapeutics (NASDAQ EBIO) traded down 2.0758% during midday trading on Tuesday, hitting $1.2926. 41,669 shares of the stock were exchanged. The firm has a market cap of $19.90 million, a PE ratio of 8.5603 and a beta of 3.31. Eleven Biotherapeutics has a 52-week low of $1.27 and a 52-week high of $5.97. The firm’s 50-day moving average is $1.51 and its 200 day moving average is $1.76.
Several hedge funds and other institutional investors have recently bought and sold shares of EBIO. Spark Investment Management LLC acquired a new position in Eleven Biotherapeutics during the second quarter worth $148,000. Vanguard Group Inc. raised its position in Eleven Biotherapeutics by 17.4% in the second quarter. Vanguard Group Inc. now owns 206,450 shares of the biopharmaceutical company’s stock worth $324,000 after buying an additional 30,600 shares during the period. Finally, Virtu KCG Holdings LLC acquired a new position in Eleven Biotherapeutics during the second quarter worth $175,000. 4.62% of the stock is owned by hedge funds and other institutional investors.
EBIO has been the subject of a number of recent research reports. Zacks Investment Research lowered shares of Eleven Biotherapeutics from a “hold” rating to a “sell” rating in a report on Friday, May 5th. ValuEngine lowered shares of Eleven Biotherapeutics from a “sell” rating to a “strong sell” rating in a report on Tuesday, June 13th.
ILLEGAL ACTIVITY NOTICE: This piece was first reported by American Banking News and is the property of of American Banking News. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright legislation. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/08/15/eleven-biotherapeutics-inc-ebio-posts-earnings-results.html.
About Eleven Biotherapeutics
Eleven Biotherapeutics, Inc is a preclinical-stage biopharmaceutical company. The Company applies its AMP-Rx platform to the discovery and development of protein therapeutics to treat diseases of the eye. The Company’s product candidate, which is still in preclinical development, is EBI-031, which was designed, engineered and generated using its AMP-Rx platform and are developing as an intravitreal injection for diabetic macular edema (DME) and uveitis.
Receive News & Ratings for Eleven Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eleven Biotherapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.